Back to School: How biopharma can reboot drug development. Access exclusive analysis here
The companies will co-develop an anti-IL-9 antibody to treat asthma, with options to include other respiratory disease
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury